Clinical trials
Acute Leukemia clinical trials
Below are recruiting acute leukemia clinical trials, each written for real people, not researchers. We’re tracking 907 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07070323RecruitingPhase 1/Phase 2
Nanobody CD5-CAR T cells for T-cell cancers
This trial tests a new treatment using your own or a donor's immune cells to fight certain T-cell cancers that haven't responded to standard therapies. It may help people who have few other options left.
Beijing, Beijing MunicipalityAges 1–70 - NCT07046078RecruitingPhase 2
Chemo, radiation, and donor transplant for older adults with high-risk AML
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Seattle, WashingtonAges 18 years+ - NCT07025564RecruitingPhase 1
MiRisten for relapsed or refractory AML
This phase 1 trial tests a new treatment called MiRisten for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07028073RecruitingPhase 1/Phase 2
New targeted treatment for newly diagnosed CBF-AML with KIT mutation
This trial tests a new targeted therapy for a specific type of leukemia (CBF-AML with a KIT gene change) in people who have not yet had treatment. The goal is to see if adding a KIT inhibitor to standard chemotherapy can improve outcomes.
Suzhou, JiangsuAges 18 years+ - NCT07022678RecruitingPhase 3
Xylitol dental wipes to reduce infection risk in childhood leukemia
This trial tests whether using xylitol dental wipes can lower the risk of bloodstream infections in children with acute myeloid leukemia (AML) who are receiving chemotherapy. If you or your child have AML and will have at least two cycles of chemo that include cytarabine, this study may help reduce infection risk.
Birmingham, AlabamaAges 1–25 - NCT07014449RecruitingPhase 1
WBC100 capsule for relapsed or refractory AML
This trial tests an experimental capsule called WBC100 for people whose leukemia has come back or hasn't responded to standard treatments. It aims to see if the drug is safe and if it can help control the disease.
Hangzhou, ZhejiangAges 18 years+ - NCT07020533RecruitingPhase 1
CMV vaccine for stem cell transplant recipients
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT07012044RecruitingPhase 1
Cedazuridine and decitabine after stem cell transplant for childhood leukemia
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
Birmingham, AlabamaAges Up to 21 years - NCT07011004RecruitingPhase 1
NK cells plus atezolizumab for acute myeloid leukemia
This trial tests combining natural killer (NK) immune cells with an immunotherapy drug (atezolizumab) for people with acute myeloid leukemia (AML) that didn't respond to or came back after prior treatments. It aims to see if this combination can help the body fight the leukemia.
Basking Ridge, New JerseyAges 18–70 - NCT07012447RecruitingPhase 2
Venetoclax with azacytidine for newly diagnosed T-cell leukemia
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
Suzhou, JiangsuAges 14 years+ - NCT06950034RecruitingPhase 1
Testing STX-0712 for advanced CMML or AML
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
Stanford, CaliforniaAges 18 years+ - NCT06928662RecruitingPhase 1/Phase 2
Chemo, radiation, and donor stem cell transplant for high-risk blood cancers
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
Seattle, WashingtonAges 18 years+ - NCT06907797Recruiting
Beta test of equity app for acute leukemia patients
This study is beta-testing a new app designed to reduce healthcare disparities among people admitted to the hospital with suspected acute leukemia. Your feedback could help make the app more helpful for future patients.
Boston, MassachusettsAges 18 years+ - NCT06882057RecruitingPhase 2/Phase 3
Treatment for newly diagnosed low-risk pediatric B-ALL
This trial tests a treatment plan for children newly diagnosed with low-risk B-cell ALL. It aims to improve outcomes while reducing side effects.
Hefei, AnhuiAges 1–18 - NCT06871410RecruitingPhase 1
Engineered immune cells for relapsed or refractory AML
This trial tests a new type of cell therapy called CD83 CAR T cells for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. These cells are designed to find and attack the leukemia cells while sparing healthy cells.
Buffalo, New YorkAges 18 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Birmingham, AlabamaAges 18–66 - NCT06846606RecruitingPhase 1
Study of AUTX-703 for advanced blood cancers
This trial tests an experimental drug, AUTX-703, for people with certain blood cancers (AML or MDS) that have returned or not improved after other treatments. The goal is to see if the drug is safe and helps control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06847269RecruitingPhase 2
CAR T cell therapy for children and young adults with CD19+ leukemia
This trial tests an immunotherapy called CAR T cells for leukemia that has come back or is hard to treat. It aims to use your own immune cells to fight the cancer.
Memphis, TennesseeAges Up to 21 years - NCT06855810RecruitingPhase 2/Phase 3
New treatment study for children with T-cell ALL
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
Hefei, AnhuiAges 1 month–18 years - NCT06839456RecruitingPhase 1/Phase 2
Stem cell addback to prevent infections after transplant
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
Philadelphia, PennsylvaniaAges 1 month–25 years - NCT06834282RecruitingPhase 1
A study of CER-1236 for certain blood cancers
This trial tests an experimental cell therapy called CER-1236 for people with acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis. It aims to see if it can help treat these cancers.
Sacramento, CaliforniaAges 18–85 - NCT06816134RecruitingPhase 2
TmBU chemo before stem cell transplant for high-risk leukemia
This clinical trial tests a new combination of chemotherapy drugs (called TmBU) before a stem cell transplant for people with high-risk or relapsed acute leukemia. The goal is to see if this conditioning regimen works better and is safe for patients who need a transplant.
Suzhou, JiangsuAges 15–65 - NCT06815003RecruitingPhase 2
Preventing Graft-Versus-Host Disease After Stem Cell Transplant
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Duarte, CaliforniaAges 18–80 - NCT06802315RecruitingPhase 2
Radiation therapy before stem cell transplant for high-risk blood cancers
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
Chicago, IllinoisAges 18–65
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute leukemia?
- Yes. Clin2 currently lists 907 recruiting acute leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.